Teva Pharm announces approval of generic protonix delayed release tablets, 20 mg and 40 mg

Co announces the FDA has granted final approval for the co's Abbreviated New Drug Application to market its generic version of Wyeth's (WYE) Protonix Delayed Release Tablets, 20 mg and 40 mg. The co's Pantoprazole Sodium DR Tablets are the AB-rated equivalent of Protonix D.R Tablets, a product indicated for short term treatment of erosive esophagitis associated with GERD, maintenance of healing of erosive esophagitis and for treatment of hypersecretory conditions. The brand product had annual sales of approx $2.5 bln for the twelve months ended June 30, 2007, based on IMS sales data.